Key Takeaways
- Revenue degrew 7% in a tough agrochemical cycle: customers took only minimum volumes, raw material prices fell, and offtake ran ~20% below forecasts, forcing the company to extend payment terms that cushioned the top line but stretched working capital.
- The order book is built on assured margin, not assured revenue timing: volume and margin are contractually locked, but revenue is a raw-material pass-through, so the real story is when those volumes actually lift.
- Working capital ballooned to 321 days and the fix is a multi-year project: sluggish offtake, 17 new product launches, and multi-step WIP all inflated inventory, while receivables rose as the company shared customer pain; management targets 180–200 days only by FY'26.
- CY'25 is the recovery bet, not FY'25: management is cautious on the first two quarters of FY'25, calling them "tepid," but says customers are far more bullish on CY'25 than CY'24, with existing-order volumes expected to catch up to CY'23 levels.
- What to watch next quarter: whether the promised "decent correction" in working capital actually begins, any hard revenue growth number for FY'25, and signs that the agrochem destocking cycle has turned.
Demand & Volume Recovery
- Agrochem destocking is still the main drag: customers started destocking first, and the company expects its own destocking to follow only in the "next few days," meaning the inventory overhang has not yet cleared.
- Offtake ran well below plan: in CY'23, actual offtake was ~20% lower than customer forecasts, with MGO typically hitting only 70–80% of forecast; two customers in particular took only minimum volumes.
- The recovery timeline is back-half weighted: management expects growth overall for CY'24 but says the first two quarters of FY'25 look "a little tepid," with improvement only in Q3 and Q4.
- CY'25 is where conviction lives: customers are saying CY'25 looks "far better" than CY'24, and management believes volumes on existing orders should be better than CY'23 by then, though it adds the caveat that these are estimates.
- Contracts have teeth but enforcement is flexible: contracts carry take-or-pay minimum offtake clauses, but the company solves shortfalls through compensation, price adjustments, different products, or higher future volumes rather than rigid enforcement.
Thakkar: "Our customers have been saying that CY'25 looks far better than CY'24 for sure. For sure. And CY'24 looks better than CY'23, also is a statement I can say."
Working Capital: The Core Problem
- Inventory days hit 321, driven by three forces: multi-step manufacturing (8–12 steps) requires WIP at every stage; 17 new molecules launched during the year added to the base; and offtake velocity was lower than expected, so inventory did not unwind.
- Receivables rose because the company chose to share pain: sluggish growth forced longer payment cycles to customers, and management says the top-line decline would have been "much larger" without that accommodation.
- No dead-inventory risk, just timing risk: management is explicit that inventory is for contracted volumes and carries no risk of obsolescence; it simply has not moved at the speed expected.
- The correction target is 180–200 days, and it is distant: management sees a "decent correction" this year but says the targeted number should only be looked at by FY'26, when sufficient revenue and volume have come in and new products have stabilized.
- Pharma will help structurally: the Pharma business is expected to carry lower inventory but higher receivables (driven by domestic India sales), with a net-net positive effect on working capital versus Agro.
Thakkar: "Slow moving in a sense is just that what I had expected them to move, they have not moved at the speed that we had expected. But is there any risk on those inventories? The answer is no. We do not see any."
Revenue Model & Margin Mechanics
- Revenue is a pass-through; EBITDA is the key metric: the pricing model builds from raw material cost through all inputs to a target margin, so volume and margin are assured while the revenue number moves with input prices.
- Raw material price swings smooth out over time: because raw material is only 30–40% of revenue, the pass-through effect on absolute EBITDA is real but modest, and over a 5–7 year horizon everything levels out.
- Stand-alone margins held steady: the slight movement in stand-alone margins was purely a product-allocation effect, not a directional shift.
- Six-month pricing contracts are now the norm: 60% of revenue sits on 6-month pricing contracts, up from 15–20% at the time of the IPO, a shift driven by raw material volatility.
- Peak revenue potential from current assets is ₹1,600–₹1,700 crores: from a volumetric standpoint, utilization is 70–75%, but the revenue ceiling from existing plants is well above current levels.
Thakkar: "For me, the key important number is EBITDA rather than my revenue in terms of a contract. Volume is assured, margins are assured."
Order Book & New Product Pipeline
- 17 new molecules launched in FY'24, with 6–8 more planned: the launches span fluorination series and LOIs or contracts signed during the year; earlier launches have already begun ramping up, with the rest scaling gradually over upcoming quarters.
- The LOI book promises ~₹1,300–₹1,400 crores per year over 6 years: this is not the only growth delta; the current portfolio, Pharma, and polymers will all contribute on top.
- LOI commercialization is a 3–4 year journey: LOIs take 18–24 months to commercialize, then another 18–24 months for full ramp-up, so the revenue impact is back-loaded.
- No single-product concentration risk: the company runs 70–80 products with no dedicated plant for any single product or customer, so no individual product can materially swing utilization or revenue.
- Japan is emerging as a major geography: two of the four new customers added in FY'24 are from Japan, and management expects Japan to become one of the major geographies in the next two years.
Portfolio Shift: Pharma, Polymers & Fluorination
- Pharma is targeted to reach ~15% of revenue: the segment will carry lower inventory but higher receivables than Agro, with a net working capital benefit; management expects Pharma to scale meaningfully as new products ramp.
- Polymers expected to deliver double-digit growth: management called out the polymer business as a significant growth driver for the next fiscal year.
- Fluorination share to grow by 5–10 percentage points: from a current ~20% base, fluorination will expand across polymers, Pharma, and Agrochem, though management declined to guide to an absolute number for FY'25 or FY'26.
- Agro and Personal Care will give up share: as Pharma and other specialties grow, Agro and Personal Care are expected to lose a few percentage points each in the mix.
Balance Sheet & Capex
- Preferential allotment proceeds used to repay ₹249 crores of long-term debt: the fund-raise was deployed during the quarter, and remaining pref and warrant money will come in over the next 12–18 months, also earmarked for debt reduction.
- No new major capex beyond the existing ₹670 crores plan: only ~₹180 crores remains to be spent, plus maintenance capex; management says it is "practically done with this plan" and FY'26 capex should be mostly maintenance.
- Free cash flow generation is the next chapter: over the next two years, revenue and EBITDA should generate free cash flow (EBITDA less tax and interest) sufficient to reduce debt, with no further working capital investment needed.
- Hybrid power investment of ₹59 crores: a 9.2 MW solar-plus-wind plant is under construction, part of the existing capex envelope.
- Tanfac HF capacity to double by next year: volumes are running to plan, domestic HF capacity is limited, and utilization is only increasing.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Working capital correction | "Decent correction" this year; target 180–200 days | FY'26 |
| Revenue growth | FY'25 will be a year of growth, but first two quarters tepid | FY'25 (Q3/Q4 weighted) |
| Stand-alone margins | Around 26%+ | Ongoing |
| Pharma revenue share | Reach ~15% of total | Not specified |
| Fluorination share | Grow by 5–10 percentage points from ~20% | Not specified |
| Polymer growth | Double-digit growth | Next fiscal year |
| Tanfac HF capacity | Double current capacity | Next year |
| New product launches | 6–8-plus additional products | Next year |
| Peak revenue potential | ~₹3,000 crores (including current capex plan) | When LOIs fully ramp |
| Capex | Balance ₹180 crores + maintenance; no external financing needed | FY'25 |
| Debt reduction | Pref/warrant proceeds to repay long-term debt | Next 12–18 months |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Operating revenue | ₹401 cr, down 16% YoY from ₹480 cr |
| EBITDA (incl. other income) | ₹105 cr, down 26% YoY from ₹142 cr |
| EBITDA margin | 25% on a consolidated basis, vs 27% in FY23 |
| Profit After Tax | ₹40 cr, degrowth of 44% YoY from ₹73 cr |
| FY24 operating revenue | ₹1,475 cr, down 8.0% YoY from ₹1,602 cr |
| FY24 EBITDA margin | 27%, equivalent to last year |
| FY24 Profit After Tax | ₹167 cr, down 23% YoY from ₹217 cr |
| New products added in Q4 | 6, summing to 17 new products in FY24 |
| New customers added in Q4 | 2, totalling 4 new customers in FY24 |
| Revenue from top 10 customers | 77% of total revenue, across 25 products |
| Segment mix: Agro / Personal Care / Pharma / Other Specialty | 65% / 17% / 9% / 9% for FY24 |
| Fluorination share of revenue | ~20% in FY24, expected to grow by at least 5 to 10 percentage points |
| LOI order book | ~₹9,000 cr, implying ~₹1,300–₹1,400 cr annual revenue over ~6 years |
| Revenue from six-month pricing contracts | ~60% of revenue, up from 15–20% at IPO |
| Stand-alone inventories | ~₹990 cr, raw material ~30%, WIP and finished goods the balance |
| Capex incurred as of 31 Mar 2024 | ₹482 cr out of the ₹670 cr plan; ₹180 cr balance capex to execute |
| Long-term debt repaid from fund-raise | ₹249 cr during the quarter |
| Stand-alone margin guidance | ~26%+ |